retinoic acid, treats acne vulgaris and keratosis pilaris
CAS：302-79-4
分子式：C20H28O2
分子量：300.4
纯度：98%
存储：Store at -20°C

Background:

Tretinoin(Aberela) is retinoic acid in pharmaceutical form and used to treat acne vulgaris and keratosis pilaris.

In cultured human mesangial cells, tretinoin increased the reduced glutathione content and the catalase activity in a dose- and time-dependent way, which then prevented the cytotoxicity of H2O2 [1].

In old male Fischer 344 rats, tretinoin inhibited the expression of TNF-β1 and osteopontin (a protein with chemotactic and cell adhesive properties) in the renal cortex [1]. In male NMRI-mice treated with 1×109 sheep red blood cells (SRBCs), tretinoin markedly inhibited cellular immunity and increased humoral immunity. Tretinoin reduced lymphocyte proliferation, NBT reduction and the secretion of interleukin-17, but increased the production of interleukin-10 [2]. In patients with facial acne, clindamycin phosphate Tretinoin Gel (CTG) (1.2% clindamycin phosphate, 0.025% tretinoin in a gel base (Velac)) was significantly more effective than 0.025% tretinoin, which relayed on the anti-inflammatory efficacy of tretinoin [3].

参考文献:
[1].  Manzano VM, Puyol MR, Puyol DR, et al. Tretinoin prevents age-related renal changes and stimulates antioxidant defenses in cultured renal mesangial cells. J Pharmacol Exp Ther, 1999, 289(1): 123-132.
[2].  Froushani SM, Galeh HE. New insight into the immunomodulatory mechanisms of Tretinoin in NMRI mice. Iran J Basic Med Sci, 2014, 17(9): 632-637.
[3].  Richter JR, F?rstr?m LR, Kiistala UO, et al. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol, 1998, 11(3): 227-233.